Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML

Journal of Cancer Epidemiology
Ricardo Ballesteros-RamírezMónica Arevalo-Zambrano

Abstract

The impact of the dose intensity administered in consolidation in Latin America is unknown. This study aimed to evaluate the relative dose intensity (RDI) in consolidation and its impact in overall survival. A retrospective study of 86 patients with AML who were diagnosed between 2010 and 2016 with a 2-year follow-up in a fourth-level Colombian hospital was carried out. Clinical characteristics were reported, Kaplan-Meier was used for estimating the overall survival, and Cox regression was used for multivariate analysis. The median overall survival (OS) was 20.83 months, and the median event-free survival (EFS) was 16.83 months. 64.3% of the patients achieved remission after the 7 + 3 chemotherapy induction treatment. Patients under 30 years of age, with white blood cell counts less than 100.000 cells/mm3 who responded to induction treatment had a better OS. Additionally, patients receiving an RDI greater than 0.75 of the planned consolidation dose had better survival. The prognostic variables with impact in the OS were the leukocyte count in peripheral blood at diagnosis, the RDI in consolidation treatment with HIDAC and the response obtained after induction. This retrospective study allowed us to know the epidemiology of AML ...Continue Reading

References

Mar 18, 2003·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·M F N RegoI Lorand-Metze
Mar 11, 2004·Blood Reviews·Krzysztof MrózekClara D Bloomfield
Aug 20, 2009·Journal of Experimental & Clinical Cancer Research : CR·Yoshiki TeradaMasayuki Hino
Jun 2, 2011·Journal of Clinical and Experimental Hematopathology : JCEH·Hiroki YamaguchiKoiti Inokuchi
Jul 14, 2012·International Journal of Hematology·Eytan M Stein, Martin S Tallman
Aug 11, 2012·Blood·Ursula CreutzigUNKNOWN AML Committee of the International BFM Study Group
May 1, 2013·The Lancet Oncology·Paul E GossGustavo Azenha
Feb 2, 2015·Revista brasileira de hematologia e hemoterapia·Sergio Lunardon PadilhaNatália Ramos Domino
Dec 4, 2015·Revista médica de Chile·Mónica FuentesPablo Ramírez

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
flow cytometry

Software Mentioned

SPSS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.